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STANDARD GAMBLE AND CONJOINT UTILITY
WEIGHTS:VALIDITY, FEASIBILITY,AND
USEFULNESS
Johnson FR1, Mauskopf J1, Hauber AB2
1Research Triangle Institute, Research Triangle Park, NC, USA;
2Parametric Research Corporation, Hatboro, PA, USA
OBJECTIVES: Compare and evaluate the conceptual and
numerical differences between standard gamble (SG) and
conjoint analysis (CA) utility weights.
METHODS: Reducing complex relationships among
health outcomes to a single utility index requires strong
assumptions. We compare and evaluate the required
assumptions for SG and CA utility weights using numer-
ical estimates from published SG weights and CA utility
estimates from a study of acute respiratory and cardio-
vascular symptoms. We analyze alternative mappings of
one index into the other, evaluate necessary assumptions
and restrictions, and compare empirical differences.
RESULTS: Differences in the underlying metrics and
information content of SG and CA utility indexes com-
plicate mapping one scale into the other. Even when the
scales can be deﬁned comparably for a given range of 
outcomes, extrapolating CA utility outside this range may
yield corresponding SG weights outside the 0–1 interval.
CA methods facilitate including other utility-relevant
health-care features, such as dosing frequency, employ
cognitive tasks more familiar to patients than the SG task,
and can be scaled in natural units such as money or time.
However, CA utility can vary nonlinearly by duration,
health-care process attributes, and individual characteris-
tics and thus cannot generally be summed across individ-
uals, health states, and time periods. If decision makers
require a simple, aggregate utility measure, they must
accept SG restrictions that break the correspondence
between measured utility and actual patient preferences.
CONCLUSIONS: CA utility weights have several con-
ceptual and empirical advantages relative to SG utility
weights. The perceived usefulness and practicality of SG
utility for constructing QALYs must be weighed against
the potential for providing decision makers with mis-
leading information about the net beneﬁts of health 
interventions.
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THE DEVELOPMENT OF A SEVERITY STAGING
SYSTEM FOR ECONOMIC EVALUATIONS OF
THE PROGRESSION OF GLAUCOMA
Walt JG1, Evans SJ2, Doyle JJ2, Casciano J2
1Allergan, Irvine, CA, USA; 2The Analytica Group, New York,
NY, USA
OBJECTIVES: In order to conduct a multi-center retro-
spective chart review, with the purposes of assessing
resource utilization and the multiple costs associated with
disease progression, a glaucoma staging system (GSS) was
developed. Since no universally accepted GSS exists, par-
ticularly one that takes into account economic consider-
ations, we tested a modiﬁed system to allow for unam-
biguous stage assignment for all patients and to evaluate
the economic impact of progressing disease severity.
METHODS: A review of currently developed GSSs was
conducted and the Bascom Palmer GSS was selected as
most adaptable for economic analyses. A modiﬁed Delphi
panel of physicians specializing in glaucoma treatment
suggested modiﬁcations to the system. Consideration was
given to practical use in retrospectively staging patients
using clinical parameters available in glaucoma charts,
with the end goal of assessing the economic impact of
treating glaucoma. Modiﬁcations were made to ensure
deﬁned stages encompassed a complete severity range
from pre-diagnosis to complete blindness. The revised
GSS was pre-tested on 30 charts at one participating
center in a retrospective chart review study and ﬁnal 
modiﬁcations were made to assure certainty in patient
classiﬁcation.
RESULTS: The ﬁnal GSS comprises six stages based 
principally on visual ﬁeld parameters. End-stage disease
was deﬁned based on poor visual acuity and inability to
perform visual ﬁelds. The ﬁnalized GSS was successfully
applied to a new group of randomly selected glaucoma
charts. The instrument was able to classify all identiﬁed
glaucoma patients from normal to end-stage disease, and
facilitated resource utilization abstraction by individual
stage.
CONCLUSIONS: An improved GSS to track progression
was designed which allows staging of patients from his-
torical chart data. This GSS may be used to monitor long-
term progression and is a useful tool for the purposes of
assessing the economic impact of glaucoma progression
in categorical stages. This GSS needs to be further tested
prospectively to determine its ultimate utility in economic
evaluations.
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MATHEMATICAL MODEL (MM) OF ANTIBIOTIC
(AB) IN VITRO SUSCEPTIBILITY (SUS) OVER
THE COMPLETE RANGE OF MINIMUM
INHIBITORY CONCENTRATION (MIC)
Chambers RB, Pankey GA
Ochsner Clinic Foundation, New Orleans, LA, USA
OBJECTIVES: Simple and complex computer MMs are
being used to research infectious disease problems. Analy-
sis of in vitro AB activity is usually limited to simple com-
parison of National Committee for Clinical Laboratory
Standards (NCCLS) tube dilution SUS and MIC90.
Similar ABs with similar MIC90s for a bacterium are
assumed equal in activity. This mimics the problem of
analyzing the survival time of patients, which is solved by
statistical methods like Kaplan Meier survival table (KM)
analysis. Using AB dilution instead of time in KM analy-
ses may identify differences in SUS that cannot be found
by traditional methods. A MM was developed to test this
assumption.
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METHODS: Computer simulations were done to illus-
trate scenarios where statistical modeling would ﬁnd 
differences between antibiotics with identical MIC50,
MIC90 and % SUS. The Base2 logarithm of AB dilution
was substituted for time in KM analyses. The KM analy-
ses detected differences in AB activity (P < 0.00005 to
0.0281) because KM compares across the entire range of
dilutions instead of only at single points like MIC50 and
MIC90. After developing the application with computer
simulation the method was tested by comparing MIC
data for piperacillin/tazobactam (PT) versus ticarcillin/
clavulanate (TC) against Klebsiella pneumoniae (4,784
isolates) and Morganella morganii (719 isolates) from a
previous study (ICAAC abstract A-57, 1996).
RESULTS: In spite of identical MIC90 and % SUS using
NCCLS criteria the MM of survival using KM analyses
showed TC superior against Klebsiella pneumoniae and
PT superior against Morganella morganii (both P <
0.00005).
CONCLUSION: Application of this Mathematical
Model and Kaplin Meier survival table analyses can dis-
cover differences in antibiotic activity hidden from tradi-
tional methods and may improve the clinical utility of in
vitro data.
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USE OF VARIOUS METHODS FOR COST
ESTIMATION IN MULTI-NATIONAL ECONOMIC
EVALUATIONS
Constenla DO
Pan-American Health Organization/World Health
Organization (PAHO/WHO), Santiago, Chile
As with many economic concepts, costs are context-
speciﬁc, and are estimated to reﬂect the nature of the
problem being addressed and the perspective of the deci-
sion-maker. Four concepts are considered when estimat-
ing costs: scope, scale, perspective and measurement
approach.
OBJECTIVE: The main objective is to assess the use and
appropriateness of different costing methods and discuss
issues surrounding the selection and construction of costs.
A cost-effectiveness analysis was performed to evaluate
the possible introduction of the pneumococcal conjugate
vaccine into vaccination programmes and is used as the
example.
METHODS: Resource use and unit cost data were col-
lected in Brazil, Chile and Uruguay separately to enable
country-speciﬁc analysis of the data. Items of health care
resource were deﬁned a priori in standardised forms. The
perspectives of the costing was the health care system 
and society. The price paid and social opportunity cost
approaches were used for unit cost estimations. Unit costs
for resource items were drawn from observational studies
or constructed from detailed costing exercises in speciﬁc
institutions.
RESULTS: Data availability between countries was vari-
able. In some cases costs could not be obtained due to
inter-country variations in clinical practice. Differences in
the organisation and delivery of care and reimbursement
of health care providers increased the variability of data
quantity and quality between countries. For some items
it proved necessary to use hospital charges as a proxy for
hospital costs. Several problems arose when estimating
hospital ward costs. Some available data sets gave a ﬁgure
for hotel costs excluding any medical costs. In the may-
ority of cases, however, it was not clear what was
included in the ward costs, which varied between 
hospitals.
CONCLUSION: It is possible to use various costing
methods in multi-national economic evaluations as long
as methods are standardised.
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METHODS FOR ASSESSING THE VALUE OF
ANTIPSYCHOTIC TREATMENT: A NEW
PERSPECTIVE FOR INTERPRETING SERVICE
UTILIZATION
Tunis SL1,Ascher-Svanum H1, Browne RA1,Wang FP1,
Kinon BJ2
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Commonly, research to assess the value of medication
therapy in schizophrenia includes the assumption that the
most effective antipsychotic agent will invariably lead to
a reduction in medical services, thereby reducing total
direct costs within a system of care.
OBJECTIVES: In this methods paper, we argue that
quantifying decreases in certain medical costs (i.e., acute
care) associated with medication treatment can be key in
decisions to purchase, prescribe, or reimburse. We also
propose that pharmacoeconomic researchers consider the
complexities of interpreting outpatient service use for
those with schizophrenia.
METHODS: We discuss the notion that increased use of
certain services may indicate that individuals are respond-
ing to medication, are engaged in their treatment plans,
and are tending to previously-neglected routine health
care needs. Additionally, we provide evidence that short-
term increases in outpatient service use may be highly
consistent with published standards for comprehensive
maintenance treatment of schizophrenia.
RESULTS: We present data illustrating the importance of
disaggregating service types when attempting to under-
stand the relationship between treatment response and
costs. Analyses should also include both a short-term 
and a longer-term perspective, to determine the extent to
which an initial “investment” in medication and perhaps
other (outpatient) treatment is likely to “pay off” through
reductions in subsequent ER and hospitalization costs,
and in individuals more able to lead productive and
enjoyable lives.
CONCLUSIONS: Research and policy focused solely on
decreases in total costs (i.e., fewer services received) can
